DUBLIN–(BUSINESS WIRE)–The “Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics: Distribution by Type of Protein degrader, Therapeutic Areas, Route of administration, Key Contributing Technologies and Key Geographies, 2021-2030” report has been added to ResearchAndMarkets.com’s offering.
Targeted protein degradation is a revolutionary pharmacological concept that presents viable drug development opportunities and is anticipated to introduce a new paradigm in modern therapeutic interventions. Due to various reasons, conventional drugs / therapies have been limited in terms of their capability to target certain proteins of pathological significance. Presently, medical researchers engaged in the development of bifunctional protein degrader-based interventions claim that this upcoming class of drugs is capable of targeting biomolecules in the human proteome, which were previously considered undruggable. The concept of targeted protein degradation revolves around the use of small molecule leads, which are capable of recruiting the ubiquitin-proteasome system (UPS) to selectively eliminate a target biomolecule.
In other words, protein degraders regulate biological pathways by selectively downregulating a target protein by degrading them; this process has been shown to be robust, more sensitive to drug-resistant targets and can regulate cellular functions that are not dependent on enzyme action. Moreover, drugs designed based on this relatively novel concept, have been shown to demonstrate a remarkable level of selectivity, high potency, oral bioavailability and differentiated pharmacology, compared to traditional enzyme inhibitors. As a result, this upcoming class of drugs has garnered significant interest within the medical science community. In fact, the growing popularity of targeted protein degradation is evident in the USD 5 billion in capital investments made into companies engaged in this field of research, since 2014.
Proteolysis targeting chimera (PROTAC), developed by Hashimoto Laboratory in 2008, was the first targeted protein degrader. The incessant efforts of researchers involved in this domain have resulted in significant progress towards understanding the physiochemical and biological properties of such bifunctional molecules. Presently, there are several other types of targeted protein degraders and molecular glues, which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer’s disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson’s disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the R&D efforts in this field are supported by DNA-encoded libraries and other in silico hit discovery and characterization tools. In the last 4-5 years, there has been a marked rise in the number of new entrants in this market.
Additionally, several big pharma players are also actively involved in this field, evaluating proprietary protein degrader-based therapeutic leads. The market has also witnessed substantial partnership activity over the last few years, with several technology developers involved in high-value licensing deals. Although, there are no approved protein degrader-based drugs / therapy products, the market is poised to witness healthy growth over the next decade.
Companies Mentioned
- 6 Dimensions Capital
- AbbVie
- Abingworth
- Advantech Capital
- Advent Life Sciences
- AIHC Capital
- Aisling Capital
- AJU IB Investment
- Alexandria Venture Investments
- Alfred Berg
- Almac Discovery
- Alpha Stem Cell Clinic
- Altitude Life Science Ventures
- AM Capital
- Amgen
- Amgen Ventures
- Amphista Therapeutics
- Amzak Health
- ARCH Venture Partners
- Arpeggio Biosciences
- Arvinas
- AstraZeneca
- Atlas Venture
- Avista Pharma Solutions
- Bain Capital Life Sciences
- Bayer
- Beactica
- BeiGene
- Bellco Capital
- Bessemer Venture Partners
- Beth Israel Deaconess Medical Center
- BeyondSpring Pharmaceuticals
- Biogen
- And Many More Companies!
Key Questions Answered
- Who are the leading industry and non-industry players engaged in this market?
- What are the key therapeutic areas for which target protein degraders are being / have been developed?
- Which geographies are the most active in conducting clinical trials on target protein degraders?
- What kind of partnership models are commonly adopted by industry stakeholders?
- Which are the leading administering institute centers supporting the research related to this domain?
- What is the trend of capital investments in the targeted protein degradation market?
- How has the intellectual property landscape in this market evolved over the years?
- How is the current and future market opportunity likely to be distributed across key market segments
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION-BASED THERAPEUTICS
5. CURRENT MARKET LANDSCAPE: TARGET PROTEIN DEGRADATION ENABLING TECHNOLOGIES
6. COMPANY PROFILES
7. CLINICAL TRIAL ANALYSIS
8. ACADEMIC GRANTS ANALYSIS
9. PUBLICATION ANALYSIS
10. PATENT ANALYSIS
11. KOL ANALYSIS
12. PARTNERSHIPS AND COLLABORATIONS
13. FUNDING AND INVESTMENT ANALYSIS
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
15. LICENSING DEAL STRUCTURE
16. EXECUTIVE INSIGHTS
17. CONCLUDING REMARKS
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/ottq2c
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900